[Anti-HBV efficacy of bifendate in treatment of chronic hepatitis B, a primary study].

Abstract

OBJECTIVE:

To investigate the anti-HBV efficacy of bifendate in treatment of chronic hepatitis B.

METHODS:

A total of 119 patients with chronic hepatitis B were randomly divided into treatment group (n = 65, aged 24 +/- 12) and control group (n = 54, aged 25 +/- 11). In the treatment group every patient was given higher doses bifendate pills (</= 12 age, 30 approximately 45 mg/d; > 12 age, 45 approximately 67.5 mg/d) for up to 12 months. Hepatic function test was performed and HBeAg, HBeAb and HBV DNA were detected at regular intervals in all patients.

RESULTS:

The serum alanine amonotransferase (ALT) decreased to normal only one month later in 70.76% of patients in the treatment group and decreased to normal at least in 2 approximately 3 months in the control group (P < 0.01). The serum conversion rates of HBeAg, HBeAb and HBV DNA in the treatment group were 44.4%, 29.3%, 38.5%, respectively, which were significantly higher than those in the control group (P < 0.01). No noticeable side effect was observed.

CONCLUSION:

Higher doses of bifendate taken for a long term has remarkable anti-HBV efficacy in treatment of chronic hepatitis B.

• Authors: Sunan Cui, Mingming Wang, Guiling Fan
• Journal: Zhonghua yi xue za zhi (Zhonghua Yi Xue Za Zhi) Vol. 82 Issue 8 Pg. 538-40 (Apr 25 2002) ISSN: 0376-2491 [Print] China
• PMID: 12133500 (Publication Type: Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Antiviral Agents
• Biphenyl Compounds
• bifendate

Topics

• Adult
• Antiviral Agents (adverse effects, therapeutic use)
• Biphenyl Compounds (adverse effects, therapeutic use)
• Female
• Hepatitis B, Chronic (drug therapy, virology)
• Humans
• Liver (drug effects, physiopathology)
• Male
• Treatment Outcome